Recruitment

Recruitment Status
Completed

Inclusion Criteria

No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm

Exclusion Criteria

Use of smokeless tobacco in any form,
Subjects with known systemic disease
Pregnant or lactating females
...
Use of smokeless tobacco in any form,
Subjects with known systemic disease
Pregnant or lactating females
Immunocompromised subjects
Known or suspected allergy to the ALN/bisphosphonate group
Subjects with aggressive periodontitis,
Those on systemic ALN/bisphosphonate therapy
Alcoholics

Summary

Conditions
Chronic Periodontitis
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 30 years and 50 years
Gender
Both males and females

Inclusion Criteria

No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm

Exclusion Criteria

Use of smokeless tobacco in any form,
Subjects with known systemic disease
Pregnant or lactating females
...
Use of smokeless tobacco in any form,
Subjects with known systemic disease
Pregnant or lactating females
Immunocompromised subjects
Known or suspected allergy to the ALN/bisphosphonate group
Subjects with aggressive periodontitis,
Those on systemic ALN/bisphosphonate therapy
Alcoholics

Tracking Information

NCT #
NCT02168543
Collaborators
Not Provided
Investigators
  • Principal Investigator: Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi
  • Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi